We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
17/12/2018 09:44 | Isn't this brilliant news ? Not only substantial cash raised at a 30% premium, long term investor on board and if trials are successful in 2019 this is back in the £s. 2019 should be transformational | kirk 6 | |
17/12/2018 09:41 | I hope Erik's departure was not connected to the rights issue | luminoso | |
17/12/2018 09:23 | Glyn's tweet this morning: Great to have a new investor who is committed to out antibiotic vision. My reply: But Glyn at a huge discount half the company for an extra 4 months added to the cash run way.However I will be supporting the motion in January & now holding half of my % of the company now looking to double up when cash allows.Bitter sweet RNS. | chrisatrdg | |
17/12/2018 08:22 | I guess I will see a number of you at the meeting in January & yes I will be supporting the motion.The RNS does at least Buy us some time & the current share price will still allow me to top up next year.Regards to all. | chrisatrdg | |
17/12/2018 07:50 | Excellent news. 32% premium. Funding sorted and all into sticky hands. | waterloo01 | |
17/12/2018 07:46 | The RNS is effectively a sale of the Company at 25p which for me is giving the company away & only takes the company to January 2020 (Only another 4 months) so will still need funds beyond that point my holding % has now halved (I think we have been here before).Clearly the Directors must have felt the Company was in 'The last chance saloon'. Edit: Currently the markets look favourably on the RNS up 19.44 % (Good for some who have recently Bought well done to you all). | chrisatrdg | |
17/12/2018 07:39 | Wow that's got to be good news surely | kirk 6 | |
17/12/2018 07:36 | "It is expected that Mr Duggan will have a shareholding of approximately 48.81% of the total voting rights of the Company immediately following completion of the Subscription." | phowdo | |
17/12/2018 07:26 | Fund raising RNS Well I am not surprised at the news as Summit needed funds to get them into 2020 & at current exchange rates values the shares at 25p (approx).Well lets see what happens at 8.00 this morning.At the moment I have it as Hold.GLA. PS Ironically I was going to ring Summit this morning to clarify the issue of funding for the C-Diff trials for next year. | chrisatrdg | |
16/12/2018 17:46 | No idea but if you like it. | waterloo01 | |
16/12/2018 15:33 | Sure, well most of it. Why? | waterloo01 | |
11/12/2018 16:11 | Hi waterloo01 I accept your comments but to have balance on what has been published today by Summit the 'Qualification' within the notes to the accounts needs mentioning.I also hope that they find the additional funds & by starting the trial next Qtr it is encouraging. I need to average down & if I have funds from my other investments I am looking to Buy between 25,000 shares & 50,000 shares but will think hard before I do (likely by March next year). I have been here before with INFA an investment which was in 'the last chance saloon' a year or so ago & is now flying hopefully Summit will be the same - further assurance of funds could take us back to £1 a share (I hope so as that is my current break even point). | chrisatrdg | |
11/12/2018 15:54 | These were some of the concerns that spooked the market at dropped this down to so low levels. We should now see a reversal as those concerns have been firmly put to bed. 1) The trial is going ahead 2) They have funds to fund a the whole trial. 3) Hold £13M cash. | zen12 | |
11/12/2018 15:43 | Chris, I spoke to them and they are quite confident they will fund the gap. I'd be very surprised if this isn't in place well before the trial starts. They have lots of options (as highlighted in the statement) but rights and or further grant would be my best guess. | waterloo01 | |
11/12/2018 15:38 | Todays RNS - My comments Below is an extract from the notes to the accounts & reflects that the Company does not have a 12 months cash runway & puts Summit back to a part qualified position a situation Summit have been in before.Within the paragraph below are the following words : 'These circumstances represent a material uncertainty which may cast and raise substantial doubt on the Groups ability to continue as a going concern.' see included below: 'The Group is evaluating various options to finance its cash needs, through a combination of some, or all, of the following: equity offerings, collaborations, strategic alliances, grants and clinical trial support from government entities, philanthropic, non-government and not-for-profit organisations and patient advocacy groups, debt financings, and marketing, distribution or licensing arrangements. Whilst the Group believes that funds would be available in this manner before the end of September 2019, there can be no assurance that the Group will be able to generate funds in this manner, on terms acceptable to the Group, on a timely basis or at all, which would impact the Groupâ€& The cash forecast has not been extended beyond September 2019 as also reported in the previous quarters accounts and this will look even worse if as at 31st January 2019 this remains the same.In the belief that Summit will find additional funds before next September the current share price makes for a Strong Buy.However Summit,in my opinion, has some 6 months to find additional funds or it will be in 'the last chance saloon'. | chrisatrdg | |
11/12/2018 15:31 | Trading in US at 21p | multiplural | |
11/12/2018 15:30 | Should be in the 20s tomorrow gla | zen12 | |
11/12/2018 13:46 | What’s up with markets - full of derampers at the minute lol. No bad news and CEO has said have enough cash for trial but still you get these guys trying to bash..an already bashed share! | zen12 | |
11/12/2018 13:37 | Agreed, impossible for any small pharma to bring a drug to market - they don't have the infrastructure and sales force on the ground for starters. Summ needs a licensing deal - can't see any big pharma interest being likely until P3 readouts available ( August 2021 earliest), so funding is going to become a real issue. They said they were 'on track' and also that they 'expected' - typical Glyn wording with a get out built in if not achieved. As per US Clinical Trials.gov website hxxps://clinicaltria 680 participants, recruitment status is not yet recruiting Estimated study start date March 2019 Estimated Primary & Study Completion date May 2021. I don't know much about Discuva - but am intrigued as to why the platform was let go for a lowly £10m if my memory serves me correctly. | lagosboy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions